China’s BeiGene pitches a $150M IPO to fund its cancer pipeline

Damian Garde

Chinese biotech is hoping to trade on the Nasdaq, filing for an IPO worth more than $ 150 million to support its of targeted drugs.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS